British Biotech(WKN 884408) in UK & USA:

Beiträge: 19
Zugriffe: 757 / Heute: 1
British Biotech(WKN 884408)  in UK & USA: Parocorp
Parocorp:

British Biotech(WKN 884408) in UK & USA:

 
03.03.00 19:21
#1
UK: über 5Mio. gehandelt + 8%
USA: aktuell uber 300000 gehandelt (!) + 20%

Bei uns: nach 14% gestern, heute + 10%...

:)))) *es wird immer breiter*

kein push! nur info halber, wenn sich jemand schlau macht, wird er wissen das BB kommen wird...

gruß

parocorp
British Biotech(WKN 884408)  in UK & USA: friedl
friedl:

Re: British Biotech(WKN 884408) in UK & USA:

 
03.03.00 19:45
#2
Stimmt, bereits + 22 % in den USA.
An Parocorp: Weißt Du, wieviel europ. Aktien von BB eine Aktie an der NASDAQ darstellen (letzter Kurs in USA: 6,5 USD, letzter Kurs in Deutschland: 0,6 EUR)?
British Biotech(WKN 884408)  in UK & USA: Parocorp
Parocorp:

Hey, jetzt + 24.71% auf 6 5/8!!!! come on baby...

 
03.03.00 20:20
#3
friedl> keinen taschenrechner zur hand? ;)

gruß

parocorp
British Biotech(WKN 884408)  in UK & USA: furby
furby:

Wieso dieser Anstieg? o.T.

 
03.03.00 20:27
#4
British Biotech(WKN 884408)  in UK & USA: Parocorp
Parocorp:

Re: British Biotech(WKN 884408) in UK & USA:

 
03.03.00 20:39
#5
NEWS von gestern:

ILEX Oncology Services Acquires U.S. Operations of British Biotech Maryland Office and Staff Expand East Coast Presence

SAN ANTONIO and OXFORD,  England, Mar 2, 2000 /PRNewswire via COMTEX/ --
ILEX(TM) Oncology Services, Inc., and British Biotech plc (Nasdaq: BBIOY) today
announced the signing of an agreement under which ILEX acquired the operations
of British Biotech's Annapolis, Maryland office.

Under the terms of the agreement, ILEX has acquired the Annapolis facility and
will provide contracted drug development services necessary to complete the
ongoing clinical development of marimastat for British Biotech in North America.
Marimastat is currently being investigated in seven Phase III studies designed
to assess the compound's potential to slow the progression of a range of solid
tumors and improve patient survival.

"In addition to an important series of contracted projects and an already
established workforce, this acquisition will allow us to interact more
effectively with our East Coast-based customers," said Michael T. Dwyer,
president of ILEX Oncology Services. "It provides closer proximity to regulatory
agencies and many of our clinical investigators. We believe that these elements
will create cost efficiencies that can be passed along to the pharmaceutical and
biotech companies utilizing our services."

The chief executive of British Biotech, Dr. Elliot Goldstein, said, "This
agreement furthers the Company's strategy of creating strong partnerships and
ensuring clinical development is conducted in an efficient and cost effective
manner. ILEX's commitment to and focus on oncology products makes this an ideal
relationship for British Biotech."

Following the agreement, management of the Maryland facility will be under the
direction of Kathleen Heck, vice president of clinical operations at ILEX. Heck
joined ILEX in 1995 and has directed client services and project management of
many of the pre-clinical and clinical studies for ILEX customers. She most
recently served as director of business development.

ILEX Oncology Services, Inc. is a wholly owned subsidiary of ILEX Oncology, Inc.
(Nasdaq: ILXO), a drug development company focused predominantly on accelerated
development of drugs for the treatment and prevention of cancer. The company
does this in two ways: by offering drug development services on a contract basis
to pharmaceutical and biotech companies through its ILEX Oncology Services
subsidiary and by advancing a diversified portfolio of anticancer drugs through
its ILEX Products subsidiary. These complementary businesses draw from the
company's core expertise: relationships with international oncology experts,
strategic alliances that provide unparalleled access to patient recruitment for
clinical trials, and simultaneous European and US drug development and approval
capabilities.

More information on ILEX Oncology, Inc. can be accessed on the World Wide Web at
www.ilexoncology.com.

British Biotech is a research and development-stage pharmaceutical company based
in Oxford, UK, which is developing drugs for the treatment of unmet medical
needs such as cancer and inflammatory and infectious diseases. The main
technology platform is inhibition of metalloenzymes which will be supplemented
through the addition of externally-generated programs.

Additional information on British Biotech may be found on the Internet at
www.britishbiotech.com.

Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because such statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include, but are
not limited to, the early stage of the companies' compounds under development;
risks in technology and product development; failure to successfully complete
clinical trials; failure to receive market clearance from regulatory agencies;
dependence on third parties and partners and those risks described in the Form
S-3 filed by ILEX Oncology, Inc. on January 7, 2000 (Commission file
#333-95353), the ILEX Annual Report on Form 10-K for the year ended December 31,
1998, in filings made by ILEX with the SEC and those in the British Biotech plc
Annual Report dated April 30, 1999. The companies disclaim any obligation to
update these forward-looking statements.


    Contact:
    Connie Wierman, Business Dev., ILEX Oncology Services, Inc., 210-949-8233
    Ann Stevens, Investor Relations, ILEX Oncology, Inc., 210-949-8230
    Deborah Sibley, Sibley & Associates Communications, 210-497-3250
    Tony Weir, British Biotech plc, 011 44 1865-781166
    Gerard Coffey, G A Kraut Company, 212-696-5600

SOURCE ILEX Oncology, Inc.


(C) 2000 PR Newswire.  All rights reserved.

www.prnewswire.com



CONTACT:          Connie Wierman, Business Dev. of ILEX Oncology Services, Inc.,
                 210-949-8233; or Ann Stevens, Investor Relations of ILEX Oncology, Inc.,
                 210-949-8230; or Deborah Sibley of Sibley & Associates Communications,
                 210-497-3250; or Tony Weir of British Biotech plc, 011 44 1865-781166; or
                 Gerard Coffey of G A Kraut Company, 212-696-5600


KEYWORD:          Texas
                 Maryland
                 England
INDUSTRY KEYWORD: HEA
                 MTC
SUBJECT CODE:     TNM

URL:              www.britishbiotech.com





...vorgestern positiver bericht in den financial times london.

...dazu stehen demnächst ergebnisse über einige phase III präparate an.

absolut unterbewertet... volle kriegskassen, neues managment und den tiefpunkt haben wir auch hinter uns, mein ich.

gruß

parocorp
British Biotech(WKN 884408)  in UK & USA: friedl
friedl:

Re: British Biotech(WKN 884408) in UK & USA:

 
03.03.00 21:36
#6
Einen Taschenrechner hätte ich schon, aber ich denke, nur zu dividieren, ohne den Kursanstieg in den USA zeitlich zu berücksichtigen (oder war der heute bei uns schon vorweggenommen?) kann vielleicht auch nicht passen.... obwohl ich mich, wenn 10:1 stimmt, schon auf die Montagskurse in EUR freue :-), denn dann sehen wir, wenn mein Taschenrechner richtig rechnet, sehr erfreulichen EUR Kursen entgegen ...
British Biotech(WKN 884408)  in UK & USA: Wulfman Jack
Wulfman Jack:

re furby

 
04.03.00 12:03
#7
anscheinend geht niemand davon aus daß sich ilex hauptberuflich damit beschäftigt, wertlose präparate durch die PHASE III tests zu bringen.

so long

Wulfman Jack
British Biotech(WKN 884408)  in UK & USA: Parocorp
Parocorp:

re wulfman

 
04.03.00 14:46
#8
selbst wenn die präparate von ilex "wertlos" sein solten, es geht doch hier um bb... und hier sind einige heiße eisen (präparate) im feuer.

gruß

parocorp
British Biotech(WKN 884408)  in UK & USA: risko
risko:

Neuigkeiten!!

 
04.03.00 15:07
#9
hursday March 2, 6:00 am Eastern Time
    Company Press Release
    SOURCE: ILEX Oncology, Inc.
    ILEX Oncology Services Acquires U.S. Operations of British Biotech
    Maryland Office and Staff Expand East Coast Presence
    SAN ANTONIO and OXFORD, England, March 2 /PRNewswire/ -- ILEX(TM) Oncology Services,
    Inc., and British Biotech plc (Nasdaq: BBIOY - news) today announced the signing of an
    agreement under which ILEX acquired the operations of British Biotech's Annapolis, Maryland
    office.

    Under the terms of the agreement, ILEX has acquired the Annapolis facility and will provide
    contracted drug development services necessary to complete the ongoing clinical development
    of marimastat for British Biotech in North America. Marimastat is currently being investigated in
    seven Phase III studies designed to assess the compound's potential to slow the progression of
    a range of solid tumors and improve patient survival.

    ``In addition to an important series of contracted projects and an already established workforce,
    this acquisition will allow us to interact more effectively with our East Coast-based customers,''
    said Michael T. Dwyer, president of ILEX Oncology Services. ``It provides closer proximity to
    regulatory agencies and many of our clinical investigators. We believe that these elements will
    create cost efficiencies that can be passed along to the pharmaceutical and biotech companies
    utilizing our services.''

    The chief executive of British Biotech, Dr. Elliot Goldstein, said, ``This agreement furthers the
    Company's strategy of creating strong partnerships and ensuring clinical development is
    conducted in an efficient and cost effective manner. ILEX's commitment to and focus on
    oncology products makes this an ideal relationship for British Biotech.''

    Following the agreement, management of the Maryland facility will be under the direction of
    Kathleen Heck, vice president of clinical operations at ILEX. Heck joined ILEX in 1995 and has
    directed client services and project management of many of the pre-clinical and clinical studies
    for ILEX customers. She most recently served as director of business development.

    ILEX Oncology Services, Inc. is a wholly owned subsidiary of ILEX Oncology, Inc. (Nasdaq:
    ILXO - news), a drug development company focused predominantly on accelerated development
    of drugs for the treatment and prevention of cancer. The company does this in two ways: by
    offering drug development services on a contract basis to pharmaceutical and biotech
    companies through its ILEX Oncology Services subsidiary and by advancing a diversified
    portfolio of anticancer drugs through its ILEX Products subsidiary. These complementary
    businesses draw from the company's core expertise: relationships with international oncology
    experts, strategic alliances that provide unparalleled access to patient recruitment for clinical
    trials, and simultaneous European and US drug development and approval capabilities.

    More information on ILEX Oncology, Inc. can be accessed on the World Wide Web at
    www.ilexoncology.com.

    British Biotech is a research and development-stage pharmaceutical company based in Oxford,
    UK, which is developing drugs for the treatment of unmet medical needs such as cancer and
    inflammatory and infectious diseases. The main technology platform is inhibition of
    metalloenzymes which will be supplemented through the addition of externally-generated
    programs.

    Additional information on British Biotech may be found on the Internet at
    www.britishbiotech.com.

    Certain statements contained herein are ``forward-looking'' statements (as such term is defined
    in the Private Securities Litigation Reform Act of 1995). Because such statements include risks
    and uncertainties, actual results may differ materially from those expressed or implied by such
    forward-looking statements. Factors that could cause actual results to differ materially from
    those expressed or implied by such forward-looking statements include, but are not limited to,
    the early stage of the companies' compounds under development; risks in technology and
    product development; failure to successfully complete clinical trials; failure to receive market
    clearance from regulatory agencies; dependence on third parties and partners and those risks
    described in the Form S-3 filed by ILEX Oncology, Inc. on January 7, 2000 (Commission file
    #333-95353), the ILEX Annual Report on Form 10-K for the year ended December 31, 1998, in
    filings made by ILEX with the SEC and those in the British Biotech plc Annual Report dated
    April 30, 1999. The companies disclaim any obligation to update these forward-looking
    statements.


    Contact:
    Connie Wierman, Business Dev., ILEX Oncology Services, Inc., 210-949-8233
    Ann Stevens, Investor Relations, ILEX Oncology, Inc., 210-949-8230
    Deborah Sibley, Sibley & Associates Communications, 210-497-3250
    Tony Weir, British Biotech plc, 011 44 1865-781166
    Gerard Coffey, G A Kraut Company, 212-696-5600

    SOURCE: ILEX Oncology, Inc.
British Biotech(WKN 884408)  in UK & USA: Wulfman Jack
Wulfman Jack:

Re: parocorp

 
04.03.00 19:26
#10
das "wertlos" war doch ironisch gemeint !

so long

Wulfman Jack
British Biotech(WKN 884408)  in UK & USA: friedl
friedl:

Re: British Biotech(WKN 884408) in UK & USA:

 
05.03.00 00:26
#11
Jetzt dürften auch die Amis auf British Biotech aufmerksam geworden sein, wenn ich mir den Verlauf an der NASDAQ ansehe - schätze, wir beginnen am Montag knapp um die 0,70 :-)
British Biotech(WKN 884408)  in UK & USA: Parocorp
Parocorp:

Re: British Biotech(WKN 884408) in UK & USA:

 
05.03.00 23:23
#12
wulfman> ok... ;)

friedl+wulfman> freu mich schon auf montag!!! (und den märz allgemein, dürften noch einiges sehen von bb)
British Biotech(WKN 884408)  in UK & USA: risko
risko:

wo kann man bitte die US- Kurse von British Biotech sehen?? und wieso.

 
06.03.00 09:41
#13
British Biotech(WKN 884408)  in UK & USA: Reboot-now
Reboot-now:

British Biotech Kursziel bis Ende 2000 -> 5 Euro o.T.

 
06.03.00 11:29
#14
British Biotech(WKN 884408)  in UK & USA: Reboot-now
Reboot-now:

Fondaufnahme für BBtech

 
06.03.00 11:44
#15
BBtech wurde in den Biotechfond der Soc. Generale mit 15% Gewichtung aufgenommen.
British Biotech(WKN 884408)  in UK & USA: risko
risko:

Re: British Biotech(WKN 884408)

 
06.03.00 11:47
#16

ONDON (dpa-AFX) - British Biotech PLC hat dem Verkauf seiner Niederlassung in Annapolis/USA an die
US-amerikanische Ilex Oncology Services Inc zugestimmt. Das teilte das Unternehmen am Donnerstag in
London mit.
Der Vertrag sieht vor, dass Ilex die klinische Entwicklung des Wirkstoffes "Marimastat" für British Biotech
in Nordamerika unterstützt. Beide Seiten betonten die positiven Effekte, die sich aus der Vereinbarung
ergäben./al/ph
British Biotech(WKN 884408)  in UK & USA: Reboot-now
Reboot-now:

Die 500% Biotech Chance ->> British Biotech o.T.

 
06.03.00 14:24
#17
British Biotech(WKN 884408)  in UK & USA: Parocorp
Parocorp:

Re: British Biotech(WKN 884408) in UK & USA:

 
06.03.00 14:47
#18
www.freerealtime.com

in london aktuell + 4.96%, über 10Mio. gehandelt, WOW!!!!!

*jipie*

gruß

parocorp
British Biotech(WKN 884408)  in UK & USA: Reboot-now

Britsh Biotech (884408) der Biotech-Hamer heute nur 7% nach ob.

 
#19


Börsenforum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen